title: Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.
authors.affiliation: Roswell Park Cancer Institute, Leukemia Section, Buffalo, NY, USA.
authors.forename: M
authors.initials: M
authors.lastname: Wetzler
authors.affiliation: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Kantarjian
authors.affiliation: Department of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
authors.forename: F E
authors.initials: FE
authors.lastname: Nicolini
authors.affiliation: Princess Margaret Cancer Centre, Allogeneic Blood and Marrow Transplant Program, Toronto, Ontario, Canada.
authors.forename: J H
authors.initials: JH
authors.lastname: Lipton
authors.affiliation: Indiana Blood and Marrow Transplantation, Hematology, Indianapolis, IN, USA.
authors.forename: L
authors.initials: L
authors.lastname: Akard
authors.affiliation: University of Bologna, Institute of Hematology and Medical Oncology, Bologna, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
authors.affiliation: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: H J
authors.initials: HJ
authors.lastname: Khoury
authors.affiliation: PharmaStat LLC, Newark, CA, USA.
authors.forename: E
authors.initials: E
authors.lastname: Li
authors.affiliation: Teva Branded Pharmaceutical Products R&D, Clinical Development, Frazer, PA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Munteanu
authors.affiliation: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: J
authors.initials: J
authors.lastname: Cortes
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006248:Harringtonines / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D012044:Regression Analysis; D016019:Survival Analysis
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D006248:Harringtonines; D000077863:Homoharringtonine